Blog
RSS FeedPosted by Michael Wonder on 11 Mar 2024
ICER publishes final evidence report on treatment for schizophrenia
11 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits ...
Posted by Michael Wonder on 08 Mar 2024
ICER to assess treatments for transthyretin amyloidosis cardiomyopathy
7 March 2024 - Report will be subject of Midwest CEPAC meeting in September 2024; draft scoping document open to ...
Posted by Michael Wonder on 01 Feb 2024
ICER publishes evidence report on treatments for paroxysmal nocturnal haemoglobinuria
1 February 2024 - Iptacopan and danicopan are two first in class agents that provide important health benefits, but there ...
Posted by Michael Wonder on 27 Jan 2024
ICER publishes evidence report on treatment for schizophrenia
25 January 2024 - KarXT has a novel mechanism of action, but there are significant uncertainties regarding long term efficacy ...
Posted by Michael Wonder on 08 Jan 2024
ICER publishes final evidence report on treatment for pulmonary arterial hypertension
8 January 2024 - Independent appraisal committee voted that sotatercept demonstrated a net health benefit when compared to background therapy; ...
Posted by Michael Wonder on 04 Jan 2024
ICER to assess treatment for myelodysplastic syndrome
3 January 2024 - Report will be subject of CTAF meeting in July 2024; draft scoping document open to public ...
Posted by Michael Wonder on 11 Dec 2023
ICER identifies most significant 2022 US drug price hikes unsupported by new clinical evidence
11 December 2023 - Of 10 high expenditure drugs that had substantial 2022 net price increases, eight were not supported by ...
Posted by Michael Wonder on 05 Dec 2023
ICER releases draft evidence report on treatment for paroxysmal nocturnal haemoglobinuria
5 December 2023 - Public comment period now open until 9 January 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 28 Nov 2023
ICER releases draft evidence report on treatment for schizophrenia
28 November 2023 - Public comment period now open until 22 December 2023; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 21 Nov 2023
ICER to assess treatment for chronic obstructive pulmonary disease
21 November 2023 - Report will be subject of Midwest England CEPAC meeting in June 2024; draft scoping document open ...
Posted by Michael Wonder on 14 Nov 2023
ICER publishes evidence report on treatment for pulmonary arterial hypertension
14 November 2023 - Sotatercept added to background therapy appears to improve clinical outcomes, but there are uncertainties on long ...
Posted by Michael Wonder on 03 Nov 2023
ICER publishes third annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
3 November 2023 - While many payers offer fair access across the domains evaluated, findings underscore the need for greater ...
Posted by Michael Wonder on 01 Nov 2023
ICER to assess MDMA assisted therapy for post-traumatic stress disorder
1 November 2023 - Report will be subject of New England CEPAC meeting in May 2024; draft scoping document open ...
Posted by Michael Wonder on 30 Oct 2023
ICER publishes final evidence report on gene therapy for metachromatic leukodystrophy
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...
Posted by Michael Wonder on 02 Oct 2023
ICER publishes special report on Eliquis and Xarelto submitted to CMS as part of public comment process on Medicare drug price negotiations
2 October 2023 - Report tailored to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding ...